TERUMO CORPORATION(4543) News

Consolidated Financial Results for the Nine Months Ended December 31, 2025〔IFRS〕

TERUMO, Apr-Dec (Cumulative 3Q) Net Income Increases by 11%, Oct-Dec Net Income Decreases by 8%

Notice Concerning Revisions to Full-Year Financial Guidance for Fiscal Year Ending March 31, 2026 (FY2025)

Consolidated Financial Results for the Six Months Ended September 30, 2025〔IFRS〕

TERUMO, Net Income Forecast for the Fiscal Year Revised Downward by 5%

Notice Concerning Partial Amendment to the Shareholder Benefit Program

Terumo to acquire OrganOx Limited, a leading innovator in organ preservation devices, marking strategic entry into the organ transplantation-related

Consolidated Financial Results for the Three Months Ended June 30, 2025〔IFRS〕

TERUMO, Apr-Jun (1Q) Net Income Increases by 23%

Notice Concerning the Determination of Details of Issuance of Stock Options (Share Warrants)

Notice Concerning Completion of Disposal of Treasury Shares as Restricted Stock Remuneration

Notice Concerning the Issuance of Stock Options (Share Warrants)

Notice Regarding Disposal of Treasury Shares as Restricted Stock Remuneration

Corporate Governance Report

Notice concerning differences in non-consolidated financial results between FY2023 and FY2024

Consolidated Financial Results for the Fiscal Year Ended March 31, 2025〔IFRS〕

TERUMO, 22% Increase in Net Income, Update Record High for Third Consecutive Term, Dividend Raised by 4 yen

Consolidated Financial Results for the Nine Months Ended December 31, 2024〔IFRS〕

TERUMO, Apr-Dec (Cumulative 3Q) Net Income Increases by 23%, Oct-Dec Net Income Increases by 19%

Notice Concerning Status and Completion of Acquisition of Own Shares, and Cancellation of Treasury Stock